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The vaginal flora is a complex microbial environment, consist-
ing of a multitude of microbial species in variable quantities and 
proportions (1, 2). This collection of microorganisms is very dis-
tinct from other anatomical regions of the human body. In pre-
menarcheal girls, Lactobacillus species are infrequent or minor 
constituents of the vaginal microbiota, with other facultative 
and strict anaerobes being in abundance. This corresponds to a 
neutral or slightly alkaline vaginal pH during early childhood. In 
healthy adult women, the microbial diversity is greatly reduced, 
with an abundance of Lactobacillus species, responsible for the 
acidification (due to lactic acid and H2O2 production) of this en-
vironment (3, 4). The colonization of the vaginal flora by lacto-
bacilli is influenced by their adhesion levels to vaginal epithelial 
cells; in addition, some of the nutrients are derived from these 
dead epithelial cells of the female hosts (and others can be found 
in some secretions of the glands in the lower reproductive tract) 
(5, 6). Following puberty, the thicker stratified epithelium and 
higher levels of glycogen in the reproductive tract of females also 
favor Lactobacillus colonization (2–4). In addition to lactobacilli, 
other microorganisms commonly identified as commensals in the 
female genital tract include Staphylococcus aureus, Streptococcus 
agalactiae (group B Streptococcus), Enterococcus faecalis, Escher-
ichia coli, and Candida albicans (7–9). After menopause, estrogen 
levels drop in the female body, dramatically affecting the vaginal 
microbiota; the pH rises to 6.0 to 8.0, corresponding to the reduc-
tion or elimination of lactobacilli and the increased colonization 
of the vaginal tract by members of the Enterobacteriaceae family, 
Gram-positive cocci, and Bacteroides and Prevotella species (fe-
cal flora) (2–6). However, if the normal vaginal flora is disrupted, 
these bacteria become pathogenic, causing vaginal discharge 
(often with a putrid odor) and other symptoms such as itching, 
which is detrimental to patients’ quality of life (QoL) (10, 11). If 
there is a multitude of bacterial species present in the vaginal 
flora, that usually corresponds to a disrupted, pathological state 
of the vaginal microbiome.
Aerobic vaginitis (AV) was first characterized in 2002 as a dis-
tinct form of vaginal inflammation from bacterial vaginosis (BV) 
(12–14). Although both conditions are characterized by the disrup-
tion of the female genital Lactobacillus flora, BV is a non-inflam-
matory condition, distinguished by the high quantity of anaerobic 
bacteria, whereas in AV there is significant inflammation and it is 
mainly caused by aerobic/facultative anaerobic bacteria (13–14).
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The main causes of AV include overpopulation of the vaginal 
flora with S. aureus, S. agalactiae, or E. coli, typically concurring 
with an increased inflammatory response or epithelial atrophy (or 
both) (15). The diagnosis of AV should be performed on the ba-
sis of wet mount microscopy, and it should be differentiated from 
BV on the basis of Nugent’s method or Gram-staining (12–13, 16). 
Antimicrobial susceptibility testing results aid the choice of the 
appropriate antibiotic; however, therapy on the basis of culture 
results only is not recommended. The prevalence of AV is around 
8 to 11% in pregnant women, and 5 to 24% in women reporting 
complaints regarding the reproductive system (12–17).
Infections of the vagina have been associated with a significant-
ly increased risk of preterm labor and low birth weight; in addi-
tion, other sequela may include pelvic inflammatory disease (PID), 
which can lead to ectopic pregnancies, tubal infertility, and other 
dysfunctions of the female reproductive system (18, 19). The role 
of bacterial infections in the vagina has also been described in the 
progression of cervical dysplasia and the transmission/acquisition 
of various viral infections (HIV and herpes simplex virus 2) (20).
The epidemiology of genitourinary pathogens varies signifi-
cantly with respect to the healthcare institution in question and 
the geographical localization (21). The emerging threat of methi-
cillin-resistant S. aureus (MRSA) infections is a grave concern for 
clinicians (22). This study describes the prevalence and antibiotic 
susceptibility patterns of S. aureus, a significant pathogen in AV, 
isolated from vaginal samples at a tertiary-care teaching hospital 
in Hungary during a 10-year study period (2008–2017).
Methods
Study design, data collection
This retrospective study was carried out using data collected be-
tween January 1st, 2008 and December 31st, 2017 at the microbi-
ology laboratory of the Albert Szent-Györgyi Clinical Center. This 
teaching hospital annually serves more than 400,000 patients in 
the Southern Great Plain of Hungary, according to the national in-
surance data (23). An electronic search in the records of the Med-
Bakter laboratory information system (LIS) for samples processed 
at our laboratory that were positive for S. aureus was conducted 
by the authors.
For the purposes of data analyses, the 10-year study period was 
divided into two 5-year periods (2008–2012 and 2013–2017, respec-
tively). In the data analysis, the authors included samples with 105 
or more colony-forming units (CFU) for S. aureus (except in cases 
where international guidelines recommend otherwise). Only the 
first isolate per patient was included in the study. In addition, S. 
aureus isolates with divergent susceptibility patterns were consid-
ered different isolates. In addition, patient data were collected re-
garding demographic characteristics (age and reason for sample 
submission as indicated on the request forms for microbiological 
analysis). The study was deemed exempt from an ethics review 
by the Institutional Review Board and informed consent was not 
required because data anonymity was maintained.
Identification of relevant isolates
Sample processing was carried out according to guidelines in rou-
tine clinical bacteriology. All culture media (5% sheep blood agar, 
chocolate agar, and eosin methylene blue agar) were incubated 
at 37 °C for 24 to 48 hours in a 5% CO2 atmosphere. If S. aureus 
was detected from the relevant samples, the plates were passed 
on for further processing. Between 2008 and 2012, presumptive 
phenotypic (biochemical reaction-based) methods and VITEK 
2 ID (bioMérieux, Marcy-l’Étoile, France) were used for bacte-
rial identification, whereas after 2013 this was complemented by 
matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Germany) 
(24). The methodology of sample preparation for MALDI-TOF MS 
measurements was described elsewhere (25).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing (AST) was performed using 
the Kirby–Bauer disk diffusion method and, when appropriate, 
E-test (Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) 
plates. In addition, for the verification of discrepant results, VITEK 
2 AST (bioMérieux, Marcy-l’Étoile, France) was also utilized. The 
interpretation of the results was based on EUCAST breakpoints 
(http://www.eucast.org). S. aureus ATCC 29213 and S. aureus ATCC 
43300 were used as quality control strains.
To evaluate the resistance trends of isolated strains, erythromy-
cin (ERI), chloramphenicol (CHL), ciprofloxacin (CIP), clindamy-
cin (CLI), doxycycline (DOX), gentamicin (GEN), and sulfameth-
oxazole/trimethoprim (SXT) were chosen as indicator antibiotics, 
based on the local antibiotic utilization data method). MRSA was 
detected using mannitol salt agar (MSA) using cefoxitin (FOX) 
disks (< 22 mm zone diameter) and PBP2' Latex Agglutination Test 
Kit (Thermo Fisher Scientific Hungary GmbH, Budapest, Hungary). 
After 2013, a combined MALDI-TOF MS and PBP2' latex agglutina-
tion protocol was introduced in our laboratory (26). MRSA-positive 
isolates were considered to be resistant to all β-lactam antibiotics. 
In the case of MRSA-positivity, susceptibility testing for additional 
antibiotics (vancomycin, VAN; linezolid, LZD; daptomycin, DAP; 
mupirocin, MUP; and fusidic acid, FZA) was performed (22). Dur-
ing data analysis, intermediate results were grouped with and re-
ported as resistant. Inducible CLI resistance was detected using 
the D test, and these strains were also reported as resistant.
Statistical analysis
Descriptive statistical analysis (including means or medians with 
ranges and percentages to characterize data) was performed us-
ing Microsoft Excel 2013 (Microsoft Corp., Redmond, WA). Statisti-
cal analyses were performed with SPSS software version 24 (IBM 
SPSS Statistics for Windows 24.0, IBM Corp., Armonk, NY), using 
the χ2 test, Student’s t-test, and Mann–Whitney U test. The nor-
mality of variables was tested using Shapiro–Wilk tests. P values 
< 0.05 were considered statistically significant.
Results
Demographic characteristics, sample types
The median age of affected patients was 31 years in both the first 
(2008–2012) and second (2013–2017) half of the study period (range 
2008–2012: 2–91 years, range 2013–2017: 9–83 years; p > 0.05), and 
the detailed age distribution of patients is presented in Figure 1. 
Most (93.95%) of the samples received were vaginal swabs, and 
5.62% were high cervical swabs, 0.29% were explanted intrauter-
ine devices (IUDs), and 0.14% were urethral swabs.
The main indications for the sample submission associated 
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with samples positive for S. aureus included vaginitis/vulvitis 
(49.79%) and high-risk pregnancy (31.02%); less common indica-
tions included nonspecific abdominal pain (1.73%), symptoms of 
menopause (1.31%), suspicion of a urinary tract infection (0.66%), 
unspecified pathology of the cervix (0.39%), amenorrhea/dysmen-
orrhea (0.33%), polycystic ovary syndrome (PCOS) or other cysts of 
the female genitourinary tract (0.30%), endometriosis (0.30%), or 
other nonspecific reasons (14.84%).
Distribution of S. aureus isolates among vaginal samples from 
women
During the 10-year surveillance period (January 1st, 2008 – De-
cember 31st, 2017), the Institute of Clinical Microbiology received 
4,012 samples from outpatient clinics and inpatient departments 
that turned out to be positive for S. aureus; after data consolida-
tion, 3,356 individual isolates were recorded (335.6 ± 89.10/year, 
range: 213–480 isolates; highest in 2016, lowest in 2008) during 
the study period (the detailed isolation frequency is presented in 
Fig. 2). A considerable but not significant increase (p = 0.182) was 
observed in the isolation frequency in the second part of the study 
period (296.80 ± 58.81 vs. 374.40 ± 103.15). In 91.4% of samples, S. 
aureus was the only pathogen isolated.
Antibiotic susceptibility trends among S. aureus strains in the 
study period
The resistance levels of the individual S. aureus isolates are sum-
marized in Table 1. The highest levels of resistance were detected 
against ERI (11.11 ± 3.65%, range: 6.76–17.17%) and CLI (10.85 ± 
3.36%, range: 6.49–15.54%), whereas resistance rates against 
DOX (2.19 ± 2.10%, range: 0–4.48%), CIP (1.50 ± 1.04%, range: 
0–3.41%), CHL (0.67 ± 0.40%, range: 0–1.90%), SXT (0.31 ± 0.81%, 
range: 0–1.61%), and GEN (0.20 ± 0.14%, range: 0–0.59%) were 
much lower in comparison. Statistically significant differences 
during the two halves of the study period could only be observed 
in the case of CLI (p < 0.001), and no such difference was noted 
for other antibiotics (p = 0.138, p = 0.685, p = 0.345, p = 0.147, p 
= 0.693, and p = 0.292 for ERI, CHL, CIP, DOX, GEN, and SXT, re-
spectively). Susceptibility to FOX was observed in 97.79% of the 
isolates over the 10-year study period.
Overall, 74 strains were detected that were MRSA-positive (FOX 
resistant and positive for PBP2' latex agglutination; the first iso-
late was recovered in 2012), representing 2.21 ± 1.91% of the iso-
lates (range 0–5.28%, highest in 2017). In addition to MRSA-pos-
itivity, 56 (75.7%) strains were also resistant to ERI, 38 (51.4%) to 
CLI, 31 (41.9%) to DOX, 11 (14.9%) to CIP, and 6 (8.1%) to GEN. No 
MRSA-positive strains were resistant to CHL and SXT; in addition, 
all MRSA strains were susceptible to the antibiotics specifically 
used for the therapy for MDR Gram-positive infections or MRSA-
decolonization (namely VAN, LZD, DAP, MUP, and FZA).
Discussion
This study reports on the epidemiological trends and resistance 
levels of S. aureus in gynecological samples in the Southern Great 
Plain of Hungary over a long surveillance period (10 years). To 
date, this is the first and longest such study in Hungary. There are 
Table 1 | Table 1. Percentage of S. aureus resistant isolates to the tested antibiotics.
Antibiotics
Study year ERI CHL CIP CLI DOX GEN SXT MRSA*
2008 8.45 % 0.00 % 0.00 % 7.98 % 6.10 % 0.00 % 0.00 % 0.00 %
2009 11.40 % 0.65 % 1.63 % 9.45 % 0.65 % 0.33 % 2.61 % 0.00 %
2010 6.76 % 0.54 % 0.27 % 6.49 % 2.43 % 0.54 % 0.27 % 0.00 %
2011 8.86 % 0.74 % 0.74 % 8.12 % 2.95 % 0.00 % 0.37 % 0.00 %
2012 9.29 % 1.24 % 3.41 % 8.36 % 3.72 % 0.31 % 0.00 % 3.41 %
2013 13.00 % 0.45 % 0.90 % 11.21 % 4.48 % 0.00 % 0.00 % 1.79 %
2014 12.50 % 0.82 % 2.45 % 11.14 % 0.27 % 0.27 % 0.00 % 3.53 %
2015 17.17 % 1.30 % 1.96 % 15.43 % 1.09 % 0.00 % 0.00 % 2.83 %
2016 7.29 % 0.63 % 1.88 % 14.79 % 0.21 % 0.00 % 0.42 % 3.13 %
2017 16.42 % 0.29 % 1.76 % 15.54 % 0.00 % 0.59 % 0.00 % 5.28 %
10-year average 11.11 % 0.67 % 1.50 % 10.85 % 2.19 % 0.20 % 0.37 % 2.21 %
SD ± 3.65 % 0.40 % 1.04 % 3.36 % 2.10 % 0.24 % 0.81 % 1.91 %
*Represents FOX resistant and PBP2’ latex agglutination-positive isolates.
ERI = erythromycin, CHL = chloramphenicol, CIP = ciprofloxacin, CLI = clindamycin, DOX = doxycycline, GEN = gentamicin, SXT =sulfamethoxazole/trimethoprim, 
MRSA = methicillin-resistant S. aureus, SD = standard deviation.
Values in boldface represent peak resistance levels.
Figure 1 | Age distribution of affected patients during study period. Figure 2 | Frequency of Staphylococcus aureus isolates in vaginal samples from 
outpatients and inpatients during the 10-year study period.
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scant data available in the literature regarding the susceptibility 
patterns of S. aureus isolates from gynecological samples, and 
therefore additional data are necessary to provide a comprehen-
sive picture of resistance trends (15, 22, 27–28). As a general rule, 
the susceptibility patterns were advantageous, and the resistance 
rates were below 20% in the case of every antibiotic tested. How-
ever, a slow and steady increase in resistance levels could be ob-
served (corresponding to MRSA isolates, which are resistant to all 
β-lactam antibiotics, apart from fifth-generation cephalosporins), 
especially since 2012, when the first MRSA isolate was reported 
(22, 29–30). In a similar study in the same geographical region and 
time period (2008–2017), the resistance trends of S. aureus were 
described from male STI samples; more than 98% of isolates were 
methicillin-susceptible, and the highest levels of resistance were 
detected against macrolides (15–28%) and clindamycin (13–30%) 
(31). S. aureus as a urinary pathogen was also characterized in the 
southern part of Hungary: in these studies, 9.8 to 11.6% of iso-
lates were MRSA between 2013 and 2017, and a numerically in-
creasing tendency was observed (unpublished results). Based on 
the results of the European Antimicrobial Resistance Surveillance 
Network (EARS-Net), the European average for the percentage of 
MRSA was 16.9%, showing a decreasing tendency with large in-
ter-country variation (1.0–44.0%) (32). Regarding Hungary, MRSA 
levels have been over 20% since the 2010s, and were fluctuating 
between 21 and 27% in the last 3 years of surveillance (2014–2017) 
(32, 33). Of course, the resistance situation is not as dramatic in 
the S. aureus isolates from vaginal samples (with the highest lev-
els of MRSA detected around 5%) compared to invasive isolates; 
nevertheless, the obvious increase in resistance should be noted.
There is no generally accepted clinical strategy for therapy for 
AV; however, several proposals have been published. The dis-
tinction between AV and BV is crucial for the choice of appropri-
ate therapy (3–13). Metronidazole has no effect on AV, unlike in 
BV and Trichomonas vaginalis infections, for which this drug is 
routinely used (6–9). Clindamycin may be considered as a valid 
therapeutic option (especially in pregnancy), whereas fluoroqui-
nolones are recommended in non-pregnant females because their 
effect on the vaginal microbiota (Lactobacillus) seems to be mini-
mal (3–13). However, antibiotic therapy should be complemented 
if the inflammation (topical steroids) or atrophy (estrogen) is pro-
nounced. In addition, the use of vaginal probiotics should also be 
encouraged. Regarding the use of estrogen, in some patient popu-
lations (breast cancer patients and postmenopausal women) its 
use is contraindicated; in these cases, a very low dose of local es-
triol should be used in combination with probiotics (3–13). Based 
on our results, the therapy for these genitourinary infections will 
not be hindered by antibiotic resistance for now; however, close 
surveillance should be performed for S. aureus isolates from all 
anatomical sites to monitor the changes in resistance trends (22). 
On the other hand, macrolides and CLI should be used with cau-
tion, and, if available, only when susceptibility to these drugs has 
been verified.
Limitations of this study must be acknowledged. First, the 
design of the study is retrospective and we could not access the 
medical records of the individual patients affected by these in-
fections. For this reason, the correlation between the existence 
of relevant risk factors and underlying illnesses (apart from age) 
and the isolation of S. aureus could not be assessed. There is a 
risk of selection bias because studies describing the prevalence 
of various infectious diseases and resistance trends are mainly 
from tertiary-care centers, which generally correspond to patients 
with more severe conditions or underlying illnesses. Finally, a 
molecular characterization of the resistance determinants in the 
individual isolates was not performed (i.e., mecA or mecC genes), 
only to the extent of FOX resistance and latex agglutination tests.
Conclusions
AV is a distinct form of vaginal inflammation from BV, predom-
inantly caused by S. aureus, S. agalactiae, and members of the 
Enterobacteriaceae family, which are abundantly present in case 
of vaginal dysbiosis. Because S. aureus is a significant pathogen 
in AV, the aim of this study was to evaluate its relevance and fre-
quency in vaginal samples at our tertiary-care teaching hospital 
during a 10-year study period (2008–2017). The highest levels 
of resistance were associated with CLI and macrolides (around 
10%), whereas MRSA-levels were below 5% up until 2017. Con-
tinuous monitoring of resistance trends and the introduction of 
antimicrobial stewardship is recommended in the therapy for AV.
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